Abstract WMP12: Acid-Formulated Malonate Improves Neuroprotection Ischemia-Selective in a Mouse Model of Ischemic Stroke

Jordan Lee,Hiran Prag,Amin Mottahedin,Mike Murphy,Thomas Krieg
DOI: https://doi.org/10.1161/str.55.suppl_1.wmp12
IF: 10.17
2024-02-01
Stroke
Abstract:Background: Malonate, a competitive inhibitor of succinate dehydrogenase, has shown much promise in ameliorating ischemia/reperfusion injury (IRI) in various diseases, including ischemic stroke. Its uptake via the monocarboxylate transporter 1 (MCT1) is enhanced by a decrease in local pH, enabling it to be preferentially taken up by ischemic tissue. We investigated whether an acid-formulated malonate could enhance uptake of malonate and, consequently, protection against stroke IRI. Methods: C57BL/6J mice were treated intravenously with either saline or malonate (640/320 mg/kg) at physiological (7.4) or low pH (6.0). Brain malonate levels were assessed by liquid chromatography-tandem mass spectrometry LC-MS/MS. For the transient middle cerebral artery occlusion (tMCAO) stroke model, mice were subjected to 30 mins ischaemia followed by either 2 hour reperfusion. Brain infarct size was assessed by TTC (2,3,5-triphenyl-2H-tetrazolium chloride) staining. Results: Malonate was acutely protective against stroke IRI with a reduction in brain infarct size from 21.98% to 6.57% after 2 hours of reperfusion. Malonate uptake into the brain in vivo dramatically increased when infused at pH 6 compared to neutral malonate. Furthermore, acid-formulation greatly enhanced the neuroprotective potency of malonate, enabling protection at a much lower dose compared to its non-acidic counterpart. Conclusions: Malonate is neuroprotective against stroke IRI. Its uptake via MCT1 and, ultimately its neuroprotective potency can be enhanced by acid formulation of the drug.
peripheral vascular disease,clinical neurology
What problem does this paper attempt to address?